We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
-0.47%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.52M
AUM Growth
-$6.16B
(-100%)
Cap. Flow
-$249M
Cap. Flow
% of AUM
-4,517.93%
Top 10 Holdings %
Top 10 Hldgs %
32.16%
Holding
158
New
15
Increased
26
Reduced
36
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Progyny
PGNY
|
+$22.4M |
| 2 |
Xenon Pharmaceuticals
XENE
|
+$19.5M |
| 3 |
Travere Therapeutics
TVTX
|
+$19.4M |
| 4 |
Ionis Pharmaceuticals
IONS
|
+$17.1M |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$17.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DexCom
DXCM
|
+$76.7M |
| 2 |
Pfizer
PFE
|
+$59.2M |
| 3 |
Iovance Biotherapeutics
IOVA
|
+$50.3M |
| 4 |
NSTG
NanoString Technologies, Inc.
NSTG
|
+$40.2M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$34.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
| $350K | 6.33% |
+2,718,735
| New | +$349K |
|
2
Bristol-Myers Squibb
BMY
$130B
| $194K | 3.51% |
2,518,700
-89,000
| -3% | -$6.78M |
|
3
Humana
HUM
$46.7B
| $171K | 3.1% |
365,700
-16,000
| -4% | -$7.12M |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $168K | 3.05% |
2,108,555
-88,000
| -4% | -$8.33M |
|
5
Boston Scientific
BSX
$68.5B
| $163K | 2.95% |
4,369,500
-230,000
| -5% | -$9.36M |
|
|
TPTX
6
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $151K | 2.74% |
2,012,250
-6,700
| -0.3% | -$298K |
|
|
SWTX
7
DELISTED
SpringWorks Therapeutics
SWTX
| $148K | 2.69% |
6,028,307
| – | – |
|
8
UnitedHealth
UNH
$389B
| $144K | 2.62% |
281,200
-13,000
| -4% | -$6.53M |
|
|
9
Pfizer
PFE
$144B
| $144K | 2.61% |
2,744,000
-1,161,500
| -30% | -$59.2M |
|
10
BioMarin Pharmaceuticals
BMRN
$12B
| $141K | 2.55% |
1,699,710
+52,680
| +3% | +$4.19M |
|
11
AbbVie
ABBV
$465B
| $122K | 2.22% |
799,800
-115,800
| -13% | -$17.7M |
|
|
SGEN
12
DELISTED
Seagen Inc. Common Stock
SGEN
| $122K | 2.2% |
687,500
+19,800
| +3% | +$2.85M |
|
13
Edgewise Therapeutics
EWTX
$4.34B
| $112K | 2.03% |
14,082,680
+138,000
| +1% | +$1.04M |
|
14
Vertex Pharmaceuticals
VRTX
$124B
| $109K | 1.98% |
387,200
-13,000
| -3% | -$3.48M |
|
15
Adicet Bio
ACET
$76.7M
| $109K | 1.97% |
465,446
| – | – |
|
|
SRRA
16
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $108K | 1.96% |
1,964,770
| – | – |
|
|
BHVN
17
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $105K | 1.9% |
719,034
| – | – |
|
18
Intuitive Surgical
ISRG
$130B
| $104K | 1.88% |
517,200
-17,000
| -3% | -$3.99M |
|
19
Arcutis Biotherapeutics
ARQT
$3.55B
| $102K | 1.85% |
4,781,646
-1,292,204
| -21% | -$26.5M |
|
|
TCDA
20
DELISTED
Tricida, Inc. Common Stock
TCDA
| $99.5K | 1.8% |
10,280,947
| – | – |
|
21
Edwards Lifesciences
EW
$48.2B
| $96.2K | 1.74% |
1,011,300
-40,000
| -4% | -$4.14M |
|
|
THRX
22
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $94.2K | 1.71% |
17,041,668
| – | – |
|
23
PMV Pharmaceuticals
PMVP
$58.7M
| $93.5K | 1.69% |
6,563,077
-292,346
| -4% | -$4.25M |
|
24
Stryker
SYK
$133B
| $87.7K | 1.59% |
441,100
-16,000
| -4% | -$3.76M |
|
25
Neurocrine Biosciences
NBIX
$18.4B
| $82.8K | 1.5% |
849,545
-25,970
| -3% | -$2.4M |
|
Similar funds
HSA
LIM
NL
BPWM
LFG
JIM
CTC
PAMP
OrbiMed's Q2 2022 Portfolio in Review
As of Q2 2022, OrbiMed held 158 positions worth $5.52M, down 100% from $6.17B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
OrbiMed withdrew a net $249M in Q2 2022, closing 15 positions and reducing 36 holdings. Its most notable exit was DexCom, an estimated $76.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier.
Against the trend, OrbiMed opened a new position in Progyny worth $18.2K.
- OrbiMed's largest Q2 2022 buy was Progyny: 625,000 shares worth $18.2K.
- OrbiMed added most to Xenon Pharmaceuticals in Q2 2022, an estimated $19.5M increase.
- OrbiMed's biggest Q2 2022 reduction was Pfizer, cutting an estimated $59.2M.
- OrbiMed fully exited DexCom in Q2 2022, selling an estimated $76.7M.
- OrbiMed's ten largest holdings make up 32% of its $5.52M portfolio in Q2 2022.
- OrbiMed opened 15 new positions and closed 15 in Q2 2022.
- OrbiMed's portfolio value fell 100% quarter-over-quarter to $5.52M.
Based on OrbiMed's 13F filing for Q2 2022, filed 15 Aug 2022.